Aino Health inks deal with 55BirchStreet to expand in German markets

Aino Health inks deal with 55BirchStreet to expand in German markets

Published: 24 minutes ago By Paroma Bhattacharya

Reports confirm that Sweden’s Aino Health and 55BirchStreet, a Germany-based digital consulting firm, have recently signed a new partnership agreement. 55BitchStreet will sell implementation services and licenses for the health manage....

Visa acquires Payworks for an integrated payment acceptance solution

Visa, the financial services company recently announced acquisition of Payworks, the Munich-based makers of payment gateway software for the POS (point of sale). The company plans to integrate cloud-based solution of Payworks into its Cyber....

Aptose commences dosing first CLL patient in phase 1 study of CG-806

Initial data from the first two cohorts has demonstrated MYC inhibition in patients with acute myelodysplastic syndrome (MDS) and myeloid leukemia (AML). The clinical-stage company Aptose Biosciences Inc. has reportedly announced that it h....

NIH and partners to start HIV vaccine trial in Europe and America

A unit of Janssen Pharmaceutical Companies of Johnson & Johnson would be sponsoring the Mosaico trial. A complementary study involving women is also currently under process in southern Africa. The National Institutes of Health (NIH....

Altimmune inks deal to acquire Spitfire Pharma and its NASH candidate

Altimmune, Inc., a clinical stage biopharma company, has recently confirmed the closing of a formerly announced acquisition of Spitfire Pharma, Inc., including the strong GLP-1/Glucagon receptor co-agonist product candidate ALT-801 for trea....

Sun Pharma launches lipid disorders drug Ezallor Sprinkle™ in the U.S.

Ezallor Sprinkle™ (rosuvastatin) capsules can be indicated for three lipid disorders in conjunction with patient’s diet. Indian pharma giant, Sun Pharmaceutical Industries Ltd. has recently announced the U.S. launch of Ezallor ....

MacroGenics, I-Mab team up to develop & market enoblituzumab in China

MacroGenics, Inc. and I-Mab Biopharma, a U.S. and China based clinical-stage biopharmaceutical company that is committed to discover and develop biologics in autoimmune and immune-oncology diseases, have recently announced that they have in....

Industry Updates